Skip to content

Bio-Rad Laboratories, Inc. BIO.B Cumulative Cost Basis

Cumulative Cost Basis at other companies

Abbott logo
AbbottABT
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s cumulative cost basis?
Bio-Rad Laboratories, Inc. (BIO.B) reported cumulative cost basis of $974.2M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s cumulative cost basis changed year-over-year?
Bio-Rad Laboratories, Inc.'s cumulative cost basis decreased by 8.0% year-over-year, from $1.06B to $974.2M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s cumulative cost basis?
Over 2 years (2020 to 2022), Bio-Rad Laboratories, Inc.'s cumulative cost basis has grown at a 1.9% compound annual growth rate (CAGR), from $1.45B to $1.51B.